Clinical trials: Graft-vs-host Disease
Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin…
- Trial name
- NCT06705062
- Testing
- reduced-dose PTCy, Standard dose PTCY
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in…
- Trial name
- ALIGHT-COPD (NCT01078623)
- Testing
- Aclidinium 200 μg / formoterol 12 μg, Formoterol 12 μg, Aclidinium 200 μg
- Where
- 10 sites in Czechia, Romania
- Volunteers
- 176 people
- Sponsor
- AstraZeneca
Stem Cell Transplant Complications
KIR Sequencing and Typing for Allograft in Nancy
The use of haploidentical donors for aHSCT has greatly increased this past decade leading to a major paradigm shift: while finding 10/10 HLA-matched donors represented the prior difficulty for decades, the current problem is…
- Trial name
- KIR-STAN (NCT04882605)
- Testing
- MHC typing, KIR typing, Assessment of KIR-based prediction scores
- Volunteers
- 156 people
- Sponsor
- Central Hospital, Nancy, France
Graft Versus Host Disease in Eye
Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the treatment of chronic graft-versus-host eye disease.
- Trial name
- NCT05294666
- Testing
- Cyclosporine, tacrolimus
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Peking University Third Hospital
Graft-vs-Host Disease, GVHD
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
This research study is trying to determine the safest dose of Brentuximab Vedotin that can be given to patients with chronic GVHD and see if chronic GVHD improves.
- Trial name
- NCT01940796
- Testing
- Brentuximab Vedotin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease
This clinical trial tests a mindfulness intervention, consisting of group sessions and an individual session, using mindfulness based stress reduction techniques, to reduce patient reported symptoms for patients with chronic…
- Conditions
- Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT07733141
- Testing
- Biospecimen Collection, Mindfulness Relaxation, Survey Administration
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- City of Hope Medical Center
Gender Differences, Musculoskeletal Assessment
Gender Differences in Musculoskeletal Assessment Methods in Patients With Chronic Mechanical Low Back Pain
This study is an observational test-retest study designed to investigate the effect of gender on core strength, balance, spinal mobility, and hamstring flexibility in patients with chronic non-specific low back pain (NS-LBP).
- Conditions
- Gender Differences, Musculoskeletal Assessment, Chronic, Low Back Pain
- Trial name
- NCT07018154
- Testing
- Musculoskeletal Assessment
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Cairo University
Graft-versus-host-disease, GVHD
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.
- Conditions
- Graft-versus-host-disease, GVHD, GVHD, Acute
- Trial name
- NCT03605927
- Testing
- BMS-986004, Sirolimus, Tacrolimus
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Graft Versus Host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with malignant hematologic diseases after single-unit unrelated cord blood transplantation (sUCBT).
- Trial name
- NCT07047456
- Testing
- Time of umbilical cord blood infusion
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Anhui Provincial Hospital
Chronic Hepatitis C Genotype 1b
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b
The purpose of this study is to confirm that combination of Narlaprevir, Ritonavir and Daclatasvir is safe and highly effective regimen in treatment-naїve patients with chronic hepatitis C (HCV) genotype 1b infection.
- Trial name
- NCT03485846
- Testing
- Narlaprevir, Ritonavir, Daclatasvir
- Where
- 4 sites in Russia
- Volunteers
- 105 people
- Sponsor
- R-Pharm
Acute Myeloid Leukemia (AML)
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60…
- Trial name
- BIG-1 (NCT02416388)
- Testing
- Idarubicin, Daunorubicin, HD Cytarabine
- Where
- 56 sites in France
- Volunteers
- 3,100 people
- Sponsor
- University Hospital, Angers
Graft vs Host Disease
Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation
Atorvastatin for prevention of acute GVHD
- Trial name
- NCT01175148
- Testing
- Atorvastatin calcium (Lipitor)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- West Virginia University
Leukemia
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
- Trial name
- NCT01357655
- Testing
- Dasatinib, BMS-833923
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Hematopoietic Stem Cell Transplantation
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
The protocols including ciclosporin A （CsA）+methotrexate (MTX) +mycophenolate Mofetil(MMF) have been widely used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation from…
- Trial name
- NCT04203108
- Testing
- ATG, CsA, MTX
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Transplant-Related Disorder
Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model
To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of adult patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset…
- Trial name
- NCT05600855
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft vs Host Disease
Chronic GVHD Response Measures Validation
The purpose of this study is to develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic Graft-versus-Host Disease (GVHD).
- Trial name
- NCT01902576
- Where
- United States
- Volunteers
- 383 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Fatigue Syndrome
Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome
Chronic fatigue syndrome is a disabling illness for which there is no specific treatment. As a group, CFS patients have disturbed sleep with frequent arousals and the sense of not having slept upon awakening.
- Trial name
- NCT00498485
- Testing
- Sodium Oxybate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Pleural Effusion, Pleurodesis
Betadine Pleurodesis Via Tunneled Pleural Catheters
The purpose of this study is to determine whether betadine (povidone-iodine) instillation during routine indwelling Tunneled Pleural Catheter (TPC) placement is efficacious in promoting pleurodesis and thus reducing the time to…
- Conditions
- Pleural Effusion, Pleurodesis, Malignant Pleural Effusion, Pleural Effusion Due to Congestive Heart Failure
- Trial name
- NCT02975921
- Testing
- Povidone-Iodine
- Sponsor
- Yale University
B-Cell Chronic Lymphocytic Leukemia
Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy
To evaluate whether CAMPATH-1H given to patients with CLL after maximum response to chemotherapy will: a) eliminate minimal residual disease (documented by flow cytometry) in patients who have achieved a complete remission (CR)…
- Trial name
- CRC005 (NCT00800943)
- Testing
- Alemtuzumab (Campath-1H)
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Chronic Lymphocytic Leukemia Research Consortium
Hepatitis C Infection
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
The purpose of this study is to compare the safety and tolerability of ascending doses of SB 9200 given for up to 14 days to subjects with chronic Hepatitis C infection.
- Trial name
- NCT01803308
- Testing
- SB9200
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 37 people
- Sponsor
- Syneos Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.